Alnylam Pharmaceuticals’ (ALNY) Neutral Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report released on Monday, Benzinga reports. They currently have a $150.00 price target on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on ALNY. HC Wainwright reissued a buy rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. Needham & Company LLC raised their target price on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the stock a buy rating in a research note on Monday, June 24th. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an overweight rating in a research note on Tuesday, June 25th. StockNews.com raised shares of Alnylam Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, April 29th. Finally, Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a buy rating in a research report on Tuesday, June 25th. Eight investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $249.95.

Alnylam Pharmaceuticals Trading Up 0.4 %

ALNY stock opened at $248.68 on Monday. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $252.87. The stock has a market cap of $31.46 billion, a price-to-earnings ratio of -92.79 and a beta of 0.37. The business’s 50-day moving average is $165.94 and its 200 day moving average is $165.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same period last year, the business earned ($1.40) earnings per share. The company’s revenue for the quarter was up 54.8% compared to the same quarter last year. As a group, equities analysts forecast that Alnylam Pharmaceuticals will post -3.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 2,103 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $485,771.97. Following the sale, the chief marketing officer now owns 15,609 shares of the company’s stock, valued at $3,605,522.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $231.00, for a total transaction of $370,755.00. Following the sale, the chief financial officer now owns 28,892 shares of the company’s stock, valued at $6,674,052. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 2,103 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $485,771.97. Following the sale, the chief marketing officer now directly owns 15,609 shares in the company, valued at approximately $3,605,522.91. The disclosure for this sale can be found here. Insiders have sold 67,357 shares of company stock worth $13,436,711 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its holdings in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the last quarter. Quent Capital LLC increased its holdings in Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the last quarter. Anchor Investment Management LLC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $38,000. Altitude Crest Partners Inc. purchased a new position in Alnylam Pharmaceuticals in the first quarter valued at $30,000. Finally, GAMMA Investing LLC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $52,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.